Cancer is the most common disease worldwide, with death often occurring as a result of metastasis. Thus, interfering with metastasis has been regarded as a promising strategy to improve the current cancer treatments. However, exploration and development of novel anti-metastatic agents remains a major challenge. Recent evidence indicated that a polysaccharide isolated from Taxus yunnanensis suppressed tumor cells proliferation. With the objective of seeking bioactive extracts, we had previously isolated, purified and characterized a complex, water-soluble polysaccharides, PSY-1, from the leaves of Taxus chinensis var. mairei, and identified its anti-neoplastic effects. In this study, we focused on the effects of PSY-1 on cancer metastasis and its mechanism(s). The results illustrated that PSY-1 effectively suppressed the migration and invasion ability of the melanoma cancer cell line B16-F10, caused down-regulation of MMP-2 and MMP-9, and that the NF-κB pathway was involved in the anti-metastatic effects imposed by PSY-1.
ChafferC.L., WeinbergR.A. (2011) A perspective on cancer cell metastasis. Science, 331, 1559–1564.
2.
TalmadgeJ.E., FidlerI.J. (2010) AACR Centennial Series: The Biology of Cancer Metastasis: historical perspective. Cancer Research, 70, 5649–5669.
3.
McGuireW.P., HoskinsW.J., BradyM.F., KuceraP.R., PartridgeE.E., LookK.Y., ClarkePearsonD.L., DavidsonM. (1996) Cyclophosphamide and cisplatin compared with Paclitaxel and Cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334, 1–6.
4.
HolmesF.A., WaltersR.S., TheriaultR.L., FormanA.D., NewtonL.K., RaberM.N., BuzdarA.U., FryeD.K., HortobagyiG.N. (1991) Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. Journal of the National Cancer Institute, 83, 1797–1805.
5.
MurphyW.K., FossellaF.V., WinnR.J., ShinD.M., HynesH.E., GrossH.M., DavillaE., LeimertJ., DhingraH., RaberM.N., KrakoffI.H., HongW.K. (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 85, 384–388.
6.
ForastiereA.A. (1994) Current and future trials of Taxol (paclitaxel) in head and neck cancer. Annals of Oncology, 5 Suppl 6, S51–54.
7.
JonesD.V., LozanoR., HoqueA., MarkowitzA., PattY.Z. (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. Journal of Clinical Oncology, 14, 2306–2310.
8.
RaoS., OrrG.A., ChaudharyA.G., KingstonD.G.I., HorwitzS.B. (1995) Characterization of the taxol binding site on the microtubule. 2-(m- azidobenzoyl) taxol photolabels a peptide (amino acids 217–231) of beta-tubulin. Journal of Biological Chemistry, 270, 20235–20238.
9.
OkanoJ.I., NagaharaT., MatsumotoK., MurawakiY. (2007) The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal regulated kinase and apoptosis. Oncology Reports, 17, 1195–1200.
10.
RudnerA.D., MurrayA.W. (1996) The spindle assembly checkpoint. Current Opinion in Cell Biology, 8, 773–780.
11.
SteinM.E., DrumeaK., AbuRasmiR., HaimN. (1997) Taxol-induced cellulitis after extravasation: a rarely reported event. American Journal of Clinical Oncology-Cancer Clinical Trials, 20, 540.
12.
HerringtonJ.D., FigueroaJ.A. (1997) Severe necrosis due to paclitaxel extravasation. Pharmacotherapy, 17, 163–165.
13.
HagiwaraH., SunadaY. (2004) Mechanism of taxane neurotoxicity. Breast Cancer, 11, 82–85.
14.
Gonzalez-AnguloA.M., Morales-VasquezF., HortobagyiG.N. (2007) Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology, 608, 1–22.
15.
YinY., YuR.M., YangW., YuanF., YanC.Y., SongL.Y. (2010) Structural characterization and anti-tumor activity of a novel heteropolysaccharide isolated from Taxus yunnanensis. Carbohydrate Polymers, 82, 543–548.
16.
WuM.B., WuY.L., ZhouJ., PanY.J. (2009) Structural characterization of a water-soluble polysaccharide with high branches from the leaves of Taxus chinensis var. mairei. Food Chemistry, 113, 1020–1024.
17.
MologniL., ClerisL., MagistroniV., PiazzaR., BoschelliF., FormelliF., Gambacorti-PasseriniC. (2009) Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. International Journal of Cancer, 124, 1990–1996.
ChambersA.F., GroomA.C., MacDonaldI.C. (2002) Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2, 563–572.
20.
HanahanD., WeinbergR.A. (2011) Hallmarks of cancer: The next generation. Cell, 144, 646–674.
21.
PeinadoH., LavotshkinS., LydenD. (2011) The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Seminars in Cancer Biology, 21, 139–146.
22.
TalmadgeJ.E., FidlerI.J. (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research, 70, 5649–5669.
23.
BerxG., van RoyF. (2009) Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspectives in Biology, 1, a003129.
24.
CavallaroU., ChristoforiG. (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nature Reviews Cancer, 4, 118–132.
25.
DuffyM.J., McGowanP.M., GallagherW.M. (2008) Cancer invasion and metastasis: changing views. Journal of Pathology, 214, 283–293.
26.
EgebladM., WerbZ. (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2, 161–174.
27.
VisseR., NagaseH. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circulation Research, 92, 827–839.
28.
JohnA., TuszynskiG. (2001) The role of matrix metalloproteinases in tumour angiogenesis and tumor metastasis. Pathology & Oncology Research, 7, 14–23.
29.
SzaboK.A., SinghG. (2005) Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. Breast Cancer Research, 7, 661–668.
30.
SellersA., ReynoldsJ.J., MeikleM.C. (1978) Neutral metallo-proteinases of rabbit bone. Separation in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans. Biochemical Journal, 171, 493–496.
31.
PellikainenJ.M., RopponenK.M., KatajaV.V., KellokoskiJ.K., EskelinenM.J., KosmaV.M. (2004) Expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 in breast cancer with a special reference to activator protein-2, Her2, and prognosis. Clinical Cancer Research, 10, 7621–7628.
32.
LeppaS., SaartoT., VehmanenL., BlomqvistC., ElomaaI. (2004) A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clinical Cancer Research, 10, 1057–1063.
33.
BérubéM., DeschambeaultA., BoucherM., GermainL., PetitclercE., GuérinS.L. (2005) MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Molecular Vision, 11, 1101–1111.
34.
SatoT., SakaiT., NoguchiY., TakitaM., HirakawaS., ItoA. (2004) Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecologic Oncology, 92, 47–56.
35.
Di NezzaL.A., MisajonA., ZhangJ., JoblingT., QuinnM.A., OstörA.G., NieG., LopataA., SalamonsenL.A. (2002) Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer, 94, 1466–1475.
36.
HuangS.Y., DeGuzmanA., BucanaC.D., FidlerI.J. (2000) Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cellular and Molecular Therapy, 6, 9–17.
37.
HuangS.Y., PettawayC.A., UeharaH., BucanaC.D., FidlerI.J. (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 20, 4188–4197.
38.
BabyJ., PickeringB.F., GopalY.N.V., Van DykeM.W. (2007) Constitutive and inducible nuclear factor-kappaB in immortalized normal human bronchial epithelial and non-small cell lung cancer cell lines. Cancer Letters, 255, 85–94.
39.
ShishodiaS., AggarwalB.B. (2002) Nuclear factor-kappaB activation: a question of life or death. Journal of Biochemistry and Molecular Biology, 35, 28–40.
40.
SethiG., SungB., AggarwalB.B. (2008) Nuclear factor-κB activation: From bench to bedside. Experimental Biology and Medicine, 233, 21–31.
41.
BondM., FabunmiR.P., BakerA.H., NewbyA.C. (1998) Synergistic up-regulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Letters, 435, 29–34.
42.
KimY., KangH., JangS.W., KoJ. (2011) Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cellular Physiology and Biochemistry, 28, 175–184.
43.
KojimaM., MorisakiT., SasakiN., NakanoK., MibuR., TanakaM., KatanoM. (2004) Increased nuclear factor-kappa B activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Research, 24, 675–681.
